Advanced biological therapies for diabetic foot ulcers

Archives of Dermatology

Volumn 146, Issue 8, 2010, Pages 857-862

  Kirsner, Robert S ^a   Warriner, Robert ^b   Michela, Michelle ^c   Stasik, Laure ^b,d   Freeman, Katherine ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Diversified Clinical Services   (United States)

^c Boston Biomedical Associates   (United States)

^d Organogenesis   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLATELET RELEASATE; PROCUREN; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG; COLLAGEN; CT-102 ACTIVATED PLATELET SUPERNATANT; DRUG MIXTURE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; WOUND DRESSING;

ARTICLE; BIOLOGICAL THERAPY; CELL THERAPY; COHORT ANALYSIS; DATA BASE; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTE; TISSUE ENGINEERING; TISSUE GRAFT; ULCER HEALING; VALIDITY; WOUND CARE; AGED; ARTIFICIAL SKIN; COMPARATIVE STUDY; DRUG EFFECTS; DRUG MIXTURE; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; THERAPEUTIC USE; TIME; TREATMENT OUTCOME; WOUND HEALING;

AGED; COHORT STUDIES; COLLAGEN; COMPLEX MIXTURES; DATABASES, FACTUAL; DIABETIC FOOT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-SIS; RETROSPECTIVE STUDIES; SKIN, ARTIFICIAL; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 77955883406     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.164     Document Type: Article

References (18)

1. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie CC, Stern MP, Boydo EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Washington, DC: Dept of Health and Human Services, 1995. DHHS publication NIH95-1468.
2. Centers for Disease Control and Prevention (CDC). History of foot ulcer among persons with diabetes - United States, 2000-2002. MMWR Morb Mortal Wkly Rep. 2003;52(45):1098-1102.
3. Centers for Disease Control and Prevention (CDC). National diabetes fact sheet United States 2003. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2003.pdf. Accessed May 20, 2008.
4. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analyses. JAMA. 1995;273(9):712-720.
5. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14(6):680-692.
6. Veves A, Falanga V, Armstrong DG, Sabolinski ML; Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of non-infected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295.
7. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebocontrolled double-blind study. Diabetes Care. 1998;21(5):822-827.
8. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24(3):483-488. (Pubitemid 32198417)
9. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115(8):627-631.
10. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care. 2002;25(10):1835-1839.
11. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2003;26(6):1696-1700.
12. Kantor J, Margolis DJ. The accuracy of using a wound care specialty clinic database to study diabetic neuropathic foot ulcers. Wound Repair Regen. 2000; 8(3):169-173.
13. Ince P, Game FL, Jeffcoate WJ. Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area. Diabetes Care. 2007;30(3):660-663.
14. Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. Curr Diab Rep. 2005;5(6):423-429.
15. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis. Diabetes Care. 1999;22(5):692-695.
16. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879-1882.
17. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg. 2001;27(4):347-351. (Pubitemid 32290859)
18. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003;21 (16):1171-1183.